Earlier, in 2008 Signum and Rohto formed a strategic alliance for the development and commercialisation of skin care products in Japan.
Under the contract, Rohto gained semi-exclusive rights to develop and sell products in Japan that contain Signum’s anti-inflammatory compound Arazine. It is closely followed by Signum’s pipeline of compounds including SIG990 which is being developed for rosacea and other inflammatory skin conditions.
Signum claimed that Arazine is the first compound from its new anti-inflammatory platform to be commercialised from its pipeline of Signal Transduction Modulators (STMs).
STMs block inflammation and neutrophil infiltration in chronic redness, acne, skin irritation, and other skin conditions by modulating G-protein signal transduction pathways.
STMs also act as antioxidants to neutralise free radicals and prevent UV damage, cellular degeneration and production of chemicals that cause further damage.